Medical equipment maker Agilent's downbeat annual forecast clouds fourth-quarter beat
Nov 25 (Reuters) -Agilent A.N forecast its annual profit below analysts' estimates on Monday, as a recovery is ongoing in the market for medical tools and equipment used in clinical studies, sending its shares down more than 2% after the bell.
Medical equipment makers such as Agilent are seeing soft demand from early-stage biotechs, as these smaller drug development companies remain cautious with investments even as recent rate cuts are expected to improve the funding environment for such clients.
The California-based company's forecast is in contrast to its larger peer Thermo Fisher TMO.N, which raised its annual profit target last month.
Agilent expects to earn an adjusted profit of $5.54 to $5.61 per share for fiscal 2025, below analysts' average estimate of $5.66 per share, according to data compiled by LSEG.
The company reported an adjusted profit per share of $1.46 for the fourth quarter, beating estimates of $1.41.
Its total quarterly sales of $1.70 billion were also above analysts' expectation of $1.67 billion.
Earlier in the day, Agilent had also said it would separate its businesses into three segments — life sciences and diagnostics markets group, applied markets group and Agilent crosslab group — as it aims to "become a nimbler company".
Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
